MarkAndrewDemitrackMD

PubMed

• Neurocognitive Effect of Biased µ-Opioid Receptor Agonist Oliceridine, a Utility Function Analysis and Comparison with Morphine.
  Laurence Moss, Hemme Hijma, Mark Demitrack, Jessica Kim, Geert Jan Groeneveld, Monique van Velzen, Marieke Niesters, Erik Olofsen, Albert Dahan> ;Anesthesiology. 2023 Dec 1
• 5 citations
  Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic-Pharmacodynamic Comparison with Morphine.
  Pieter Simons, Rutger van der Schrier, Maarten van Lemmen, Simone Jansen, Kiki W K Kuijpers, Monique van Velzen, Elise Sarton, Todd Nicklas, Cathy Michalsky, Mark A De...> ;Anesthesiology. 2023 Mar 1
• 6 citations
  Neurostructural Differences in Adolescents With Treatment-Resistant Depression and Treatment Effects of Transcranial Magnetic Stimulation.
  Bhedita J Seewoo, Jennifer Rodger, Mark A Demitrack, Karen L Heart, John D Port, Jeffrey R Strawn, Paul E Croarkin> ;The International Journal of Neuropsychopharmacology. 2022 Aug 16
• 3 citations
  Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events.
  Kit N Simpson, Michael J Fossler, Linda Wase, Mark A Demitrack, Todd L Wandstrat> ;Expert Review of Pharmacoeconomics & Outcomes Research. 2022 Jun 1
• 2 citations
  Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk.
  Alexander Burashnikov, Hector Barajas-Martinez, Robert H. Cox, Mark A. Demitrack, Michael J. Fossler, Michael S. Kramer, Robert Kleiman, Peter R. Kowey, Charles Antzel...> ;Heart Rhythm. 2021 Sep 2
• 6 citations
  Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Contro...
  Gregory B. Hammer, Ashish Khanna, Cathy Michalsky, Linda Wase, Mark A. Demitrack, Roderick J. A. Little, Michael J. Fossler, Sabry Ayad> ;Pain and Therapy. 2021 Aug 5
• 4 citations
  Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain.
  Kit N. Simpson, Michael J. Fossler, Linda Wase, Mark A. Demitrack> ;Journal of Comparative Effectiveness Research. 2021 Jul 9
• 13 citations
  Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label T...
  Marek Brzezinski, Gregory B. Hammer, Keith A. Candiotti, Sergio D. Bergese, Peter H. Pan, Michael H. Bourne, Cathy Michalsky, Linda Wase, Mark A. Demitrack, Ashraf S. ...> ;Pain and Therapy. 2021 Jan 21
• 36 citations
  Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial.
  Paul E. Croarkin, Ahmed Z. Elmaadawi, Scott Aaronson, G. Randolph Schrodt, Richard C. Holbert, Sarah Verdoliva, Karen Heart, Mark A. Demitrack, Jeffrey R. Strawn> ;Neuropsychopharmacology. 2021 Jan 1
• 17 citations
  Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo ...
  Timothy L Beard, Cathy Michalsky, Keith A. Candiotti, Paul Rider, Linda Wase, Ashraf S. Habib, Mark A. Demitrack, Michael J. Fossler, Eugene R. Viscusi> ;Pain and Therapy. 2021 Jun 1
• 15 citations
  Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis
  Sergio D. Bergese, Richard D Berkowitz, Paul Rider, Martin Ladouceur, Suzanne Griffith, Alvaro Segura Vasi, Kristina Cochrane, Linda Wase, Mark A. Demitrack, Ashraf S....> ;Pain Research & Management. 2020 Oct 24
• 17 citations
  Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.
  Albert Dahan, C Jan van Dam, Marieke Niesters, Monique van Velzen, Michael J Fossler, Mark A Demitrack, Erik Olofsen> ;Anesthesiology. 2020 Sep 1
• 13 citations
  A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250,...
  Michael J. Fossler, Virginia D. Schmith, Stephen A. Greene, Lauren R. L. Lohmer, Michael S. Kramer, Kelly A. Arscott, Ian E. James, Mark A. Demitrack> ;CNS Drugs. 2020 Aug 1
• 20 citations
  Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration...
  Sabry Ayad, Mark A. Demitrack, David A. Burt, Cathy Michalsky, Linda Wase, Michael J. Fossler, Ashish Khanna> ;Clinical Drug Investigation. 2020 Aug 1
• 7 citations
  Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance.
  Jeffrey R. Strawn, Scott Aaronson, Ahmed Z. Elmaadawi, G. Randolph Schrodt, Richard C. Holbert, Sarah Verdoliva, Karen Heart, Mark A. Demitrack, Paul E. Croarkin> ;Journal of Child and Adolescent Psychopharmacology. 2020 May 4
• 96 citations
  APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ-Opioid Receptor, for Manag...
  Neil Singla, Franck Skobieranda, David G. Soergel, Monica Y Salamea, David A. Burt, Mark A. Demitrack, Eugene R. Viscusi> ;Pain Practice. 2019 Jun 24
• 57 citations
  The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF)
  Harold A. Sackeim, Scott Aaronson, Mark Bunker, Charles R. Conway, Mark A. Demitrack, Mark S. George, Joan Prudic, Michael E. Thase, A. John Rush> ;Journal of Psychiatric Research. 2019 Jun 1
• Erratum to “Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite ...
  Noah S. Philip, David L. Dunner, Sheila M. Dowd, Scott Aaronson, David G. Brock, Linda L. Carpenter, Mark A. Demitrack, Sarit Hovav, Philip G. Janicak, Mark S. George> ;Brain Stimulation. 2016 Jul 1
• 49 citations
  Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized P...
  Noah S. Philip, David L. Dunner, Sheila M. Dowd, Scott Aaronson, David G. Brock, Linda L. Carpenter, Mark A. Demitrack, Sarit Hovav, Philip G. Janicak, Mark S. George> ;Brain Stimulation. 2016 Mar 1
• 96 citations
  A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefi...
  David L. Dunner, Scott Aaronson, Harold A. Sackeim, Philip G. Janicak, Linda L. Carpenter, Terrence Boyadjis, David G. Brock, Dafna Bonneh-Barkay, Ian A. Cook, Karl La...> ;The Journal of Clinical Psychiatry. 2014 Sep 16
• 23 citations
  Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: Acute and six month outcomes
  H. B. Solvason, Mustafa M. Husain, Paul B. Fitzgerald, Peter B. Rosenquist, William V. McCall, James Kimball, William S. Gilmer, Mark A. Demitrack, Sarah H. Lisanby> ;Brain Stimulation. 2014 Mar 1
• 24 citations
  Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice
  Philip G. Janicak, David L. Dunner, Scott Aaronson, Linda L. Carpenter, Terrence Boyadjis, David G. Brock, Ian A. Cook, Karl Lanocha, Hugh B. Solvason, Dafna Bonneh-Ba...> ;CNS Spectrums. 2013 Dec 1
• 21 citations
  Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder
  Peter B. Rosenquist, Andrew D. Krystal, Karen Heart, Mark A. Demitrack, W. Vaughn McCall> ;Psychiatry Research. 2013 Jan 30
• 24 citations
  Linking disease symptoms and subtypes with personalized systems-based phenotypes: A proof of concept study
  Kirstin Aschbacher, Emma K. Adam, Leslie J. Crofford, Margaret E. Kemeny, Mark A. Demitrack, Amos Ben-Zvi> ;Brain, Behavior, and Immunity. 2012 Oct 1
• 98 citations
  Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-mo...
  Philip G. Janicak, Ziad Nahas, Sarah H. Lisanby, H. Brent Solvason, Shirlene Sampson, William M. McDonald, Lauren B. Marangell, Peter B. Rosenquist, W. Vaughn McCall, ...> ;Brain Stimulation. 2010 Oct 1
• Join now to see all